

Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary

18 March 2022 | News

Dr. Hansen to provide clinical input to product development process; strengthen strategic partnerships with U.S. networks Second leadership announcement for U.S. subsidiary in a month



Seegene Inc. , South Korea's leading molecular diagnostics company, announced the appointment of Dr. Glen Hansen, as the Head of Scientific and Medical Affairs of its United States subsidiary, Seegene Technologies. In this role, Dr. Hansen will provide clinical input to the development process of new products and initiate product and disease state knowledge to targeted medical and scientific thought leaders.

Dr. Hansen has decades of real-world and clinical experience as a microbiologist specializing in molecular diagnostics and medical microbiology. Prior to joining Seegene, he was the Medical Director of the Microbiology and Molecular Diagnostics Laboratory at Hennepin County Medical Center in Minneapolis and the University of Minnesota School of Medicine. Dr. Hansen graduated with honors from the University of Saskatchewan where he earned dual bachelor's degrees in Microbiology and Immunology. He later received his Ph.D. in Clinical Microbiology. His post-doctoral experience includes a fellowship in Molecular Diagnostics (New York University/New York Public Health Research Institute) and in Medical Microbiology and Public Health Microbiology (University of Washington).

Dr. Hansen's appointment marks the second leadership announcement for the U.S. subsidiary in less than a month. In late February, Seegene appointed Richard Creager, Ph.D., as the CEO to help solidify its U.S. business and deliver on the company's global strategy as a molecular diagnostics platform company, through product development, M&As and strategic alliances.